Invetx, a Boston, MA-based animal health biopharmaceutical company, raised $15m in Series A financing.
The round was led by founding investor Anterra Capital. With this financing, global biologics CDMO WuXi Biologics joined Invetx as an investor and a research collaborator.
The company intends to use the funds to drive clinical entry of a first therapeutic candidate and preclinical development of its broader pipeline of protein-based therapeutics.
Led by Juergen Horn, Ph.D., chief executive officer, Invetx is building a premier biotechnology platform for protein-based therapeutics in animal health. The company is collaborating with contract manufacturing leader WuXi Biologics to leverage its global development expertise and manufacturing capabilities and has also established an animal health collaboration with Vancouver-based AbCellera, which will use its proprietary platform for antibody discovery to accelerate preclinical activities.